Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Should l Buy SNDX?
Source: SeekingAlpha
Total Revenue $45.9 million for the third quarter, representing strong 21% growth over the prior quarter. The growth is attributed to the launch metrics for Revuforj and Niktimvo, which are addressing major unmet patient needs.
Net Revenue for Revuforj $32 million in the third quarter, up 12% from the prior quarter. Growth occurred despite approximately 1/3 of patients temporarily pausing treatment to receive a stem cell transplant. Indicators of demand remain strong with approximately 25% growth in total prescriptions and new patient starts.
Net Revenue for Niktimvo $45.8 million in the third quarter, a robust 27% increase over the prior quarter. The growth is attributed to rapid and durable improvements observed in patients and increasing adoption among healthcare providers.
Collaboration Revenue from Niktimvo $13.9 million for the third quarter. Niktimvo continues to be a positive cash flow contributor to Syndax, with a margin contribution expected to grow as sales increase.
Cash Position $456 million in cash, equivalents, and short- and long-term investments as of September 30, 2025. The company expects to reach profitability with current funds on hand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNDX
Wall Street analysts forecast SNDX stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.880
Low
27.00
Averages
39.11
High
56.00
Current: 23.880
Low
27.00
Averages
39.11
High
56.00
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Syndax Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Syndax Pharmaceuticals granted inducement awards for up to 81,600 shares of common stock to three new employees, aimed at attracting and retaining key talent, thereby enhancing the company's innovative capabilities and market competitiveness.
- Vesting Schedule: The stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date, and the remaining shares vesting monthly over the next 36 months, ensuring continued employee contributions during their service.
- Innovative Drug Pipeline: Syndax's pipeline includes FDA-approved drugs Revuforj® and Niktimvo™, indicating the company's ongoing investment and research capabilities in cancer treatment, aimed at meeting market demands for new therapies.
- Clinical Trial Advancement: The company is conducting several clinical trials to unlock the full potential of its pipeline, further driving innovation in cancer treatment and improving patient outcomes and quality of life.
See More
Syndax (SNDX) Q4 2025 Earnings Call Transcript
See More
Syndax Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Syndax Pharmaceuticals reported total revenue of $172.4 million for 2025, with Revuforj net revenue reaching $124.8 million, reflecting a 38% year-over-year increase, indicating strong market demand and product uptake that is expected to drive continued growth.
- Outstanding Niktimvo Performance: Niktimvo generated $152 million in net revenue in the first 11 months of 2025, surpassing the benchmark set by Sanofi's REZUROCK, demonstrating Syndax's competitive edge and rapid market share expansion in the new drug sector.
- Sustained R&D Investment: With $394 million in cash and equivalents at the end of 2025, the company is well-positioned to meet its funding needs for future R&D and market expansion, supporting its strategic goal of targeting a total addressable market exceeding $10 billion.
- Clinical Trial Progress: Enrollment for the MAXPIRe Phase II trial has been completed, with topline data expected in Q4 2026, which will provide critical data support for the company's further development in specific disease areas.
See More
Syndax Pharma Reports Q4 Loss and Revenue Surge
- Financial Performance: Syndax Pharma reported a Q4 net loss of $68.01 million, or $0.78 per share, which is an improvement from last year's loss of $94.17 million and $1.10 per share, indicating progress in loss control.
- Revenue Surge: The company's Q4 revenue soared to $68.73 million, a staggering 794.9% increase from $7.68 million last year, reflecting strong product sales and market demand recovery, potentially laying the groundwork for future profitability.
- Improved Profitability: Although still in the red, the reduced loss compared to last year suggests that Syndax Pharma has made strides in cost management and operational efficiency, which may attract more investor interest in its growth potential.
- Market Outlook: With rapid revenue growth and shrinking losses, Syndax Pharma's competitive position in the biopharmaceutical sector is expected to strengthen, particularly in new product launches and market expansion, potentially leading to greater market share.
See More
Syndax Pharmaceuticals Reports Q4 Earnings and 2026 Outlook
- Earnings Report: Syndax Pharmaceuticals reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.23, indicating challenges in profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $68.7 million, a staggering 794.5% increase year-over-year, surpassing estimates by $3.95 million, reflecting significant market acceptance of its products and laying a foundation for future growth.
- Expense Forecast: Syndax anticipates total research and development plus selling, general, and administrative expenses to reach approximately $400 million in 2026, excluding an estimated $50 million in non-cash stock compensation, which could exert pressure on the company's cash flow.
- Market Outlook: Despite profitability challenges, Syndax's early market performance signals continued growth potential, particularly with product launches in 2026, which may attract increased investor interest.
See More
Syndax Pharmaceuticals Q4 Earnings Preview
- Earnings Announcement Date: Syndax Pharmaceuticals (SNDX) is set to announce its Q4 earnings on February 26th after market close, with a consensus EPS estimate of -$0.58, reflecting a 47.3% year-over-year improvement, indicating potential profitability enhancement.
- Significant Revenue Growth Expected: The anticipated revenue for Q4 is $64.75 million, representing a staggering 743.1% year-over-year increase, which underscores the company's remarkable growth in market demand and product sales, potentially bolstering investor confidence.
- Performance Beat Record: Over the past year, SNDX has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting a degree of stability in financial performance and potential upside for investors.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen four upward revisions and two downward adjustments, while revenue estimates have experienced four upward revisions and one downward, reflecting fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
See More
Syndax Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Syndax Pharmaceuticals granted inducement awards for up to 81,600 shares of common stock to three new employees, aimed at attracting and retaining key talent, thereby enhancing the company's innovative capabilities and market competitiveness.
- Vesting Schedule: The stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date, and the remaining shares vesting monthly over the next 36 months, ensuring continued employee contributions during their service.
- Innovative Drug Pipeline: Syndax's pipeline includes FDA-approved drugs Revuforj® and Niktimvo™, indicating the company's ongoing investment and research capabilities in cancer treatment, aimed at meeting market demands for new therapies.
- Clinical Trial Advancement: The company is conducting several clinical trials to unlock the full potential of its pipeline, further driving innovation in cancer treatment and improving patient outcomes and quality of life.
See More
Syndax (SNDX) Q4 2025 Earnings Call Transcript
See More
Syndax Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Syndax Pharmaceuticals reported total revenue of $172.4 million for 2025, with Revuforj net revenue reaching $124.8 million, reflecting a 38% year-over-year increase, indicating strong market demand and product uptake that is expected to drive continued growth.
- Outstanding Niktimvo Performance: Niktimvo generated $152 million in net revenue in the first 11 months of 2025, surpassing the benchmark set by Sanofi's REZUROCK, demonstrating Syndax's competitive edge and rapid market share expansion in the new drug sector.
- Sustained R&D Investment: With $394 million in cash and equivalents at the end of 2025, the company is well-positioned to meet its funding needs for future R&D and market expansion, supporting its strategic goal of targeting a total addressable market exceeding $10 billion.
- Clinical Trial Progress: Enrollment for the MAXPIRe Phase II trial has been completed, with topline data expected in Q4 2026, which will provide critical data support for the company's further development in specific disease areas.
See More
Syndax Pharma Reports Q4 Loss and Revenue Surge
- Financial Performance: Syndax Pharma reported a Q4 net loss of $68.01 million, or $0.78 per share, which is an improvement from last year's loss of $94.17 million and $1.10 per share, indicating progress in loss control.
- Revenue Surge: The company's Q4 revenue soared to $68.73 million, a staggering 794.9% increase from $7.68 million last year, reflecting strong product sales and market demand recovery, potentially laying the groundwork for future profitability.
- Improved Profitability: Although still in the red, the reduced loss compared to last year suggests that Syndax Pharma has made strides in cost management and operational efficiency, which may attract more investor interest in its growth potential.
- Market Outlook: With rapid revenue growth and shrinking losses, Syndax Pharma's competitive position in the biopharmaceutical sector is expected to strengthen, particularly in new product launches and market expansion, potentially leading to greater market share.
See More
Syndax Pharmaceuticals Reports Q4 Earnings and 2026 Outlook
- Earnings Report: Syndax Pharmaceuticals reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.23, indicating challenges in profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $68.7 million, a staggering 794.5% increase year-over-year, surpassing estimates by $3.95 million, reflecting significant market acceptance of its products and laying a foundation for future growth.
- Expense Forecast: Syndax anticipates total research and development plus selling, general, and administrative expenses to reach approximately $400 million in 2026, excluding an estimated $50 million in non-cash stock compensation, which could exert pressure on the company's cash flow.
- Market Outlook: Despite profitability challenges, Syndax's early market performance signals continued growth potential, particularly with product launches in 2026, which may attract increased investor interest.
See More
Syndax Pharmaceuticals Q4 Earnings Preview
- Earnings Announcement Date: Syndax Pharmaceuticals (SNDX) is set to announce its Q4 earnings on February 26th after market close, with a consensus EPS estimate of -$0.58, reflecting a 47.3% year-over-year improvement, indicating potential profitability enhancement.
- Significant Revenue Growth Expected: The anticipated revenue for Q4 is $64.75 million, representing a staggering 743.1% year-over-year increase, which underscores the company's remarkable growth in market demand and product sales, potentially bolstering investor confidence.
- Performance Beat Record: Over the past year, SNDX has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting a degree of stability in financial performance and potential upside for investors.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen four upward revisions and two downward adjustments, while revenue estimates have experienced four upward revisions and one downward, reflecting fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
See More
